Oxford Immunotec Global PLC (NASDAQ:OXFD) – Stock analysts at Piper Jaffray Companies boosted their Q2 2019 earnings estimates for shares of Oxford Immunotec Global in a report released on Thursday, May 9th. Piper Jaffray Companies analyst W. Quirk now forecasts that the company will post earnings of ($0.02) per share for the quarter, up from their previous forecast of ($0.04). Piper Jaffray Companies currently has a “Overweight” rating on the stock. Piper Jaffray Companies also issued estimates for Oxford Immunotec Global’s Q3 2019 earnings at ($0.03) EPS, Q4 2019 earnings at ($0.09) EPS, FY2019 earnings at ($0.19) EPS, Q1 2020 earnings at ($0.12) EPS, Q2 2020 earnings at $0.03 EPS, Q3 2020 earnings at $0.02 EPS, Q4 2020 earnings at ($0.06) EPS and FY2020 earnings at ($0.13) EPS.
Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.14. The firm had revenue of $14.79 million during the quarter, compared to analysts’ expectations of $13.74 million. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 16.30%. The company’s revenue for the quarter was up 26.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.40) earnings per share.
Shares of OXFD opened at $16.08 on Monday. The stock has a market cap of $434.17 million, a price-to-earnings ratio of 31.53 and a beta of 0.32. Oxford Immunotec Global has a 12 month low of $11.66 and a 12 month high of $19.19.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Polar Capital LLP increased its holdings in shares of Oxford Immunotec Global by 2.3% during the fourth quarter. Polar Capital LLP now owns 2,557,973 shares of the company’s stock worth $32,691,000 after buying an additional 58,351 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Oxford Immunotec Global by 2.4% during the third quarter. BlackRock Inc. now owns 1,310,098 shares of the company’s stock worth $21,264,000 after buying an additional 30,774 shares in the last quarter. FIL Ltd acquired a new stake in shares of Oxford Immunotec Global during the first quarter worth approximately $5,586,000. Bellevue Group AG increased its holdings in shares of Oxford Immunotec Global by 38.2% during the fourth quarter. Bellevue Group AG now owns 306,606 shares of the company’s stock worth $3,918,000 after buying an additional 84,769 shares in the last quarter. Finally, Penn Capital Management Co. Inc. increased its holdings in shares of Oxford Immunotec Global by 11.7% in the fourth quarter. Penn Capital Management Co. Inc. now owns 302,984 shares of the company’s stock valued at $3,872,000 after purchasing an additional 31,704 shares in the last quarter. 88.96% of the stock is owned by institutional investors.
In other news, CEO Peter Wrighton-Smith sold 10,600 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $16.68, for a total transaction of $176,808.00. Following the completion of the sale, the chief executive officer now owns 445,138 shares of the company’s stock, valued at $7,424,901.84. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $16.05, for a total transaction of $48,150.00. Following the sale, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $48,150. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,700 shares of company stock valued at $464,558. Company insiders own 6.61% of the company’s stock.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Featured Story: How is net asset value different from market price?
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.